繁體中文
返回
- English
- 繁體中文
- 简体中文
- 深色
- 淺色
立即開戶
CVS Health | 8-K: Current report
CVS Health | 8-K: Current report
西維斯健康 | 8-K:重大事件
牛牛AI助理已提取核心訊息
CVS Health announced the early results of its $1.77 billion maximum tender offer for multiple series of senior notes. As of December 13, 2024, significant portions of the notes have been tendered, with acceptance rates ranging from 14.56% to 70.61% across different series.The company has elected to accept for purchase and make payment for validly tendered notes on December 18, 2024, subject to acceptance priority levels. Due to reaching the maximum tender offer amount, no additional notes are expected to be purchased after the early settlement date.The total consideration for each $1,000 principal amount will be calculated to yield a sum equal to the applicable U.S. Treasury reference security yield plus a fixed spread. Holders of accepted notes will receive the total consideration, including a $30 per $1,000 early tender payment, plus accrued interest.
CVS Health announced the early results of its $1.77 billion maximum tender offer for multiple series of senior notes. As of December 13, 2024, significant portions of the notes have been tendered, with acceptance rates ranging from 14.56% to 70.61% across different series.The company has elected to accept for purchase and make payment for validly tendered notes on December 18, 2024, subject to acceptance priority levels. Due to reaching the maximum tender offer amount, no additional notes are expected to be purchased after the early settlement date.The total consideration for each $1,000 principal amount will be calculated to yield a sum equal to the applicable U.S. Treasury reference security yield plus a fixed spread. Holders of accepted notes will receive the total consideration, including a $30 per $1,000 early tender payment, plus accrued interest.
西維斯健康宣佈其17.7億美元最高買斷要約對多系列高級票據的早期結果。截至2024年12月13日,大量票據已被投標,不同系列的接受率範圍在14.56%到70.61%之間。公司已決定在2024年12月18日接受購買有效投標的票據,並進行付款,具體按照接受優先級水平。由於已達到最高買斷要約金額,預計在早期結算日期後不會購買額外的票據。每$1,000本金金額的總對價將計算爲相應的美國財政參考證券收益加上一個固定的利差。接受的票據持有人將收到總對價,包括每$1,000的$30早期投標支付,以及應計利息。
西維斯健康宣佈其17.7億美元最高買斷要約對多系列高級票據的早期結果。截至2024年12月13日,大量票據已被投標,不同系列的接受率範圍在14.56%到70.61%之間。公司已決定在2024年12月18日接受購買有效投標的票據,並進行付款,具體按照接受優先級水平。由於已達到最高買斷要約金額,預計在早期結算日期後不會購買額外的票據。每$1,000本金金額的總對價將計算爲相應的美國財政參考證券收益加上一個固定的利差。接受的票據持有人將收到總對價,包括每$1,000的$30早期投標支付,以及應計利息。
有用
沒用
譯文內容由第三人軟體翻譯。
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
資訊熱榜
更新時間